Practice question

Abzyme-directed prodrug therapy also known as ADAPT aims to combine tumor-targeting specificity of antibodies with catalytic turnover allowing one antibody molecule to activate many prodrug molecules amplifying effect. Conventional systemic chemotherapy distributes throughout body causing dose limiting myelosuppression, alopecia, mucositis due to toxicity to rapidly dividing normal tissues such as bone marrow and gastrointestinal epithelium. Prodrug strategy masks cytotoxic warhead with cleavable moiety ester, carbamate, glucuronide, or phosphate rendering molecule 100 to 1000 fold less toxic, highly water soluble improving pharmacokinetics, stable in circulation half-life hours to days. Abzyme accumulates at tumor expressing carcinoembryonic antigen CEA, HER2, or prostate specific membrane antigen through high affinity binding 10^-9 M retained for days while unbound antibody cleared via liver. Subsequent intravenous prodrug administration encounters catalytic antibody at malignant site, enzymatic cleavage liberates active drug doxorubicin, nitrogen mustard, or camptothecin analog locally achieving intratumoral concentrations tenfold higher than systemic dosing permits with minimal plasma exposure. Catalytic nature distinguishes from stoichiometric antibody-drug conjugates that deliver one drug per antibody. Unlike bacterial enzyme ADEPT using carboxypeptidase G2 eliciting neutralizing antibodies after one cycle, humanized abzymes reduce immunogenicity permitting repeated dosing, improving therapeutic index and reducing systemic adverse effects while maintaining efficacy.